Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-224-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.09 million
Profitability
Miscellaneous
Employees70
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Organovo (NASDAQ:ONVO) Frequently Asked Questions
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
How were Organovo's earnings last quarter?
Organovo Holdings Inc (NASDAQ:ONVO) posted its earnings results on Thursday, August, 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The medical research company earned $0.67 million during the quarter, compared to analyst estimates of $0.77 million. Organovo had a negative return on equity of 69.51% and a negative net margin of 831.99%. View Organovo's Earnings History.
When is Organovo's next earnings date?
What price target have analysts set for ONVO?
1 Wall Street analysts have issued 12 month price objectives for Organovo's shares. Their forecasts range from $2.50 to $2.50. On average, they anticipate Organovo's share price to reach $2.50 in the next year. This suggests a possible upside of 825.9% from the stock's current price. View Analyst Price Targets for Organovo.
What is the consensus analysts' recommendation for Organovo?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Organovo.
Has Organovo been receiving favorable news coverage?
News articles about ONVO stock have trended somewhat negative on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Organovo earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Organovo.
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include Axcella Health (AXLA), Aptose Biosciences (APTO), Windtree Therapeutics (WINT), Nantkwest (NK), Jounce Therapeutics (JNCE), Gamida Cell (GMDA), Polarityte (PTE), Allena Pharmaceuticals (ALNA), Fennec Pharmaceuticals (FENC), Vical (VICL), Erytech Pharma (ERYP), Brainstorm Cell Therapeutics (BCLI), Genocea Biosciences (GNCA), Curis (CRIS) and Idera Pharmaceuticals (IDRA).
What other stocks do shareholders of Organovo own?
Who are Organovo's key executives?
Organovo's management team includes the folowing people:
- Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
- Mr. Craig Kussman, Chief Financial Officer (Age 60)
- Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
- Mr. Paul Gallant, Gen. Mang. (Age 54)
- Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
Who are Organovo's major shareholders?
Organovo's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (16.22%), Nikko Asset Management Americas Inc. (8.37%), Renaissance Technologies LLC (4.09%), Vanguard Group Inc. (3.56%), Sumitomo Mitsui Trust Holdings Inc. (3.16%) and BlackRock Inc. (1.60%). View Institutional Ownership Trends for Organovo.
Which major investors are selling Organovo stock?
ONVO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., D. E. Shaw & Co. Inc., Bank of New York Mellon Corp, Vanguard Group Inc., Morgan Stanley and Northern Trust Corp. View Insider Buying and Selling for Organovo.
Which major investors are buying Organovo stock?
ONVO stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Renaissance Technologies LLC, ARK Investment Management LLC, Paloma Partners Management Co, Jane Street Group LLC and Advisor Group Inc.. View Insider Buying and Selling for Organovo.
How do I buy shares of Organovo?
Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Organovo's stock price today?
One share of ONVO stock can currently be purchased for approximately $0.27.
How big of a company is Organovo?
Organovo has a market capitalization of $35.18 million and generates $3.09 million in revenue each year. The medical research company earns $-26,640,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Organovo employs 70 workers across the globe.View Additional Information About Organovo.
What is Organovo's official website?
How can I contact Organovo?
Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]
MarketBeat Community Rating for Organovo (NASDAQ ONVO)
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
